Press Releases May 21, 2026 08:45 AM

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

MiMedx Group to Present at Craig-Hallum's 23rd Annual Institutional Investor Conference

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
MDXG

MiMedx Group, Inc., a leader in wound care and healing solutions, announced its participation in the upcoming Craig-Hallum 23rd Annual Institutional Investor Conference where senior management will engage with investors.

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MDXG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • MiMedx will participate in a prominent investor conference to discuss corporate strategy and updates.
  • The company specializes in products for managing chronic wounds, burns, and surgical applications.
  • This event offers an opportunity to reinforce relationships with institutional investors and attract potential investment.

MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com


Risks

  • The conference participation itself does not guarantee new business or revenue growth, leading to uncertain immediate impact on stock price.
  • Competitive pressures in the wound care and regenerative medicine sectors may affect future performance.
  • Broader healthcare regulatory changes could impact product approvals and reimbursement affecting MiMedx's operations.

More from Press Releases

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease Jun 9, 2026 Philips Future Health Index 2026: AI is already saving clinicians time and delivering measurable impact in healthcare Jun 9, 2026 Skyworks Unveils Next-Generation EV Gate Driver Platform to Improve Inverter Efficiency and Reduce System Cost Jun 9, 2026 EHang Reports First Quarter 2026 Unaudited Financial Results Jun 9, 2026 onsemi Introduces GaNEXUS Gallium Nitride Power Portfolio Jun 9, 2026